Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.22B | 1.25B | 1.34B | 932.64M | 534.82M | 499.63M |
Gross Profit | 579.51M | 772.59M | 112.62M | 588.60M | 322.54M | 303.12M |
EBITDA | 607.44M | 295.55M | 780.51M | 555.62M | 287.60M | 274.18M |
Net Income | -391.06M | -654.49M | -278.26M | -106.00M | 14.32M | 19.19M |
Balance Sheet | ||||||
Total Assets | 10.50B | 10.65B | 12.64B | 13.85B | 4.26B | 3.81B |
Cash, Cash Equivalents and Short-Term Investments | 25.72M | 68.92M | 25.70M | 60.96M | 13.18M | 15.30M |
Total Debt | 5.10B | 4.96B | 5.30B | 5.70B | 1.92B | 1.71B |
Total Liabilities | 5.35B | 5.35B | 5.71B | 6.17B | 2.07B | 1.86B |
Stockholders Equity | 5.08B | 5.23B | 6.82B | 7.57B | 2.19B | 1.95B |
Cash Flow | ||||||
Free Cash Flow | 205.53M | 252.64M | 268.79M | 109.20M | 131.94M | 376.13M |
Operating Cash Flow | 473.25M | 501.62M | 499.82M | 272.75M | 232.63M | 470.09M |
Investing Cash Flow | 920.65M | 900.92M | 349.14M | 1.63B | -562.47M | -555.17M |
Financing Cash Flow | -1.39B | -1.36B | -884.22M | -1.86B | 327.72M | 99.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $7.47B | 28.28 | 8.36% | 3.69% | 50.84% | 104.44% | |
77 Outperform | $3.54B | 23.84 | 10.49% | 4.82% | 6.87% | 7.23% | |
74 Outperform | $4.43B | 24.28 | 6.66% | 6.50% | 6.89% | 240.70% | |
72 Outperform | $6.90B | ― | -1.51% | 2.47% | 11.62% | ― | |
61 Neutral | $5.79B | ― | -7.59% | 7.10% | -7.16% | 23.40% | |
53 Neutral | $1.25B | 2.61 | -2.60% | 5.63% | -2.14% | -129.62% | |
51 Neutral | $2.43B | ― | -25.97% | 7.90% | 27.66% | 18.03% |
Healthcare Realty Trust reported its second-quarter 2025 results, highlighting a GAAP net loss of $0.45 per share and a normalized FFO of $0.41 per share. The company saw improvements in operating metrics, such as a 5.1% growth in cash NOI and a 40 basis point increase in occupancy to 90%. The company executed new and renewal leases totaling 1.5 million square feet and completed asset sales worth $182.4 million. Leadership changes included the appointment of Peter Scott as President and CEO, and a reduction in board size from 12 to 7 members. The company also extended its $1.5 billion revolving credit facility to mature in 2030 and published a strategic plan to enhance shareholder value.
The most recent analyst rating on (HR) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.
On July 31, 2025, Healthcare Realty Trust announced a new credit facility agreement, effective July 25, 2025, which replaces its existing credit arrangements. This new facility includes a $1.5 billion unsecured revolving credit and five term loan tranches totaling $1.115 billion, with extended maturity dates and interest rates tied to the borrower’s credit ratings. The agreement aims to enhance financial flexibility and maintain favorable credit terms, potentially impacting the company’s financial operations and its stakeholders.
The most recent analyst rating on (HR) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.
On June 18, 2025, Healthcare Realty Trust announced the voluntary retirement of five directors from its Board, reducing its size from 12 to 7 members. This strategic move aligns the Board’s size with industry standards and reinforces the company’s commitment to best practices in corporate governance. The changes are expected to enhance shareholder engagement and drive value, with the remaining directors focused on strengthening stakeholder relationships and capitalizing on strong industry fundamentals.
The most recent analyst rating on (HR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.
On May 20, 2025, Healthcare Realty Trust‘s Board of Directors appointed Peter A. Scott as a director and increased the board size to 12 members, with plans to reduce it in the future. Mr. Scott, who became the company’s President and CEO on April 15, 2025, will serve on the Capital Allocation Committee. At the annual stockholders’ meeting on May 20, 2025, several directors were elected, and key proposals, including the ratification of BDO USA, P.C. as the independent accounting firm and executive compensation, were approved.
The most recent analyst rating on (HR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.